Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups — Robert Z. Orlowski (2019) | RDL Network
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups
Article 2019 en
Authors
RO
Robert Z. Orlowski
PM
Philippe Moreau
RN
Rubén Niesvizky
Abstract
1 min read
With median follow-up of approximately 44 months, clinically meaningful improvements in OS were observed with Kd56 versus Vd, including in all subgroups examined. The Kd56 safety profile was consistent with previous analyses.
Robert Z. Orlowski, Philippe Moreau, Heinz Ludwig, Albert Oriol Rocafiguera, Wee Joo Chng, Hartmut Goldschmidt, Zhao Yang, Amy Kimball, Meletios A Dimopoulos
Thierry Façon, Rubén Niesvizky, María‐Victoria Mateos, David S. Siegel, Cara A. Rosenbaum, Sara Bringhen, Katja Weisel, P. Joy Ho, Heinz Ludwig, Shaji Kumar, Kenneth T. Wang, Mihaela Obreja, Zhao Yang, Zandra Klippel, Khalid Mezzi, Amanda Goldrick, Christina Tekle, Meletios A Dimopoulos
Heinz Ludwig, Philippe Moreau, Meletios A Dimopoulos, María‐Victoria Mateos, Martin Kaiser, Roman Hájek, Shibao Feng, Kim Cocks, Jaqueline Buchanan, Katja Weisel
Ecenur Guder Arslan, Kwee Yong, T. John Martin, Meletios A Dimopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Philippe Moreau
Paul G. Richardson, Aurore Perrot, Jesús F. San Miguel, Meral Beksaç, Ivan Špıčka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Shang‐Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Rick Zhang, Franck Dubin, Mony Chenda Morisse, Kenneth C. Anderson
Discussion(0)
No comments yet. Be the first to comment.